NGM Biopharmaceuticals Advances in Cancer Cachexia Treatment with NGM120 Study

Ngm Biopharmaceuticals, Inc. ((NGM)) announced an update on their ongoing clinical study.

NGM Biopharmaceuticals, Inc. is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia. The study aims to evaluate the efficacy, safety, and tolerability of NGM120 in treating cancer cachexia in colorectal cancer patients, a condition characterized by severe weight loss and muscle wasting, which significantly impacts patient quality of life and survival.

The study tests the drug NGM120, administered subcutaneously in varying doses and schedules, against a placebo. NGM120 is designed to mitigate the effects of cancer cachexia, potentially improving patient outcomes and quality of life.

This interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.

The study began in June 2025, with an estimated primary completion date yet to be announced. The last update was submitted on June 25, 2025, indicating ongoing recruitment and progress.

The successful development of NGM120 could significantly impact NGM Biopharmaceuticals’ stock performance by positioning the company as a leader in addressing cancer cachexia, a major unmet medical need. This could also influence investor sentiment positively, particularly if interim results show promise. Competitors in the oncology space will likely monitor these developments closely.

The study is currently recruiting, with further updates available on the ClinicalTrials portal.